Core Viewpoint - The SPRUTRITION quercetin capsules, marketed as a dietary supplement for "dissolving nodules," face scrutiny due to questionable efficacy claims and potential violations of advertising laws in China [1][10]. Group 1: Product Issues - The SPRUTRITION quercetin capsules were found to have misleading advertising claims, including the assertion of "dissolving nodules," which lacks clinical evidence [1][10]. - After being taken down from the SPRUTRITION US Spruce live stream, the product was reintroduced under a different name while still promoting the same efficacy claims [1][9]. - The product's online presence includes vague promotional content that suggests health benefits without providing concrete evidence [5][9]. Group 2: Regulatory Concerns - Legal experts highlight that the marketing of quercetin as a treatment for nodules violates multiple articles of the Advertising Law of the People's Republic of China, which prohibits misleading claims and disease treatment assertions [9][10]. - The product's advertising fails to comply with regulations that restrict health claims for dietary supplements, particularly regarding disease prevention and treatment [10][11]. Group 3: Ingredient Efficacy - The product contains several ingredients, including 400mg of PPC, 200mg of quercetin, and others, but there is insufficient clinical evidence to support their effectiveness in treating benign nodules [10][11]. - Quercetin is recognized for its antioxidant properties but lacks high-quality clinical trials demonstrating its efficacy in reducing or eliminating nodules [10][11]. - Other ingredients, such as summer grass extract and cat's claw, have limited research backing their claimed benefits, and their effectiveness remains uncertain [11][12]. Group 4: Company Background - SPRUTRITION is registered under Yunshan Hengmao (Beijing) Enterprise Management Co., Ltd., which was established in November 2017 and operates primarily in business services [12]. - The company holds the SPRUTRITION trademark, with a registration period extending from May 28, 2022, to May 27, 2032 [12].